Deals
Pfizer-Allergan Deal May Be Imperiled by U.S. Inversion Rules
- Treasury also targets related-party debt in new proposals
- Secretary Lew says regulators exploring further measures
Pfizer-Allergan and the New U.S. Tax Inversion Rule
This article is for subscribers only.
As the U.S. took tougher steps Monday to limit the tax-cutting power of corporate inversions, analysts said the new rules may put a planned $160 billion merger between Pfizer Inc. and Allergan Plc in jeopardy.
By Tuesday, Allergan shares were trading at $224.78 at 8:30 a.m. in New York, below their price of $271.57 on Oct. 26, before reports that the two drug-makers were in talks about a deal.